---
title: "Sandoz Inc. v. Amgen Inc."
citation: "582 U.S. ___"
docket: "15-1039"
publishdate: "2017-06-12"
argdate: "2017-04-26"
justices:
- 1991thomas
advocates:
- "Deane E. Maynard"
- "Anthony A. Yang"
- "Seth P. Waxman"
roles:
- "on behalf of the Petitioner in No. 15-1039 (Sandoz Inc.)"
- "Assistant to the Solicitor General, for the United States, as amicus curiae, supporting the Petitioner in No. 15-1039 (Sandoz Inc.)"
- "on behalf of the Petitioners in No. 15-1195 (Amgen Inc., et al.)"
tags:
topics:
summary: "In this suit involving the Biologics Price Competition and Innovation Act of 2009’s patent-dispute regime, 42 U.S.C. § 262(l)(2)(A)’s disclosure requirement is not enforceable by federal injunction; the availability of a state-law injunction to enforce that provision should be determined on remand; and § 262(l)(8)(A)’s notice of commercial marketing may be provided prior to obtaining licensure."
---
In this suit involving the Biologics Price Competition and Innovation Act of 2009’s patent-dispute regime, 42 U.S.C. § 262(l)(2)(A)’s disclosure requirement is not enforceable by federal injunction; the availability of a state-law injunction to enforce that provision should be determined on remand; and § 262(l)(8)(A)’s notice of commercial marketing may be provided prior to obtaining licensure.

